How should we use convalescent plasma therapies for the management of COVID-19?

Erica M. Wood, Lise J. Estcourt, Zoe K. McQuilten

Research output: Contribution to journalReview ArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Convalescent plasma (CP) from blood donors with antibodies to severe acute respiratory syndrome coronavirus 2 may benefit patients with COVID-19 by providing immediate passive immunity via transfusion or by being used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), transfusion volume, and administration timing remain to be determined. Preliminary COVID-19 CP safety data are encouraging, but establishing the clinical efficacy of CP requires an ongoing international collaborative effort. Preliminary results from large, high-quality randomized trials have recently started to be reported.

Original languageEnglish
Pages (from-to)1573-1581
Number of pages9
JournalBlood
Volume137
Issue number12
DOIs
Publication statusPublished - 25 Mar 2021

Cite this